Pfizer and Roivant launch autoimmune specialist Priovant

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune

Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

Sumitomo Dainippon bolts on pipeline via $3bn Roivant allian...